Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment Naïve Asian Patients With Non-valvular Atrial Fibrillation "XaMINA"


Phase Results N/A

Eligibility Criteria

Inclusion Criteria

- Female and male patients aged 19 years or older (Korea) and aged 20 years or older (Taiwan)
- Diagnosis of NVAF
- Patients for whom the decision to initiate treatment with rivaroxaban is made as per physician's routine treatment practice
- Treatment naïve regarding stroke prevention for atrial fibrillation
- Signed informed consent

Exclusion Criteria

- Contraindications for rivaroxaban according to the local market authorization/summary of product characteristics (SmPC)
- Patients participating in an investigational program with interventions outside of routine clinical practice